SAN FRANCISCO, March 07, 2023 (GLOBE NEWSWIRE) -- Augmedix Inc. (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, today announced that Manny Krakaris, Chief Executive Officer, and Paul Ginocchio, Chief Financial Officer will attend and present at the Oppenheimer 33rd Annual Healthcare Conference taking place virtually on March 13 – 15, 2023.
Management will host a live webcast presentation at 2:00 p.m. ET on Tuesday, March 14, 2023, and will also conduct one-on-one investor meetings throughout the conference.
Details for the live webcast presentation are below.
| Date: | Tuesday, March 14 |
| Time: | 2:00 p.m. ET |
| Webcast: | /webcast/oppenheimer27/register.aspx?conf=oppenheimer27&page=augx&url=https://wsw.com/webcast/oppenheimer27/augx/2795849 |
Attending investors interested in meeting with Augmedix management can contact their Oppenheimer representative. Investors can also contact the Augmedix IR team at This email address is being protected from spambots. You need JavaScript enabled to view it. to learn more.
About Augmedix
Augmedix, Inc. (Nasdaq: AUGX) delivers industry-leading, ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners.
Augmedix is on a mission to help clinicians and patients form a human connection at the point of care without the intrusion of technology. Augmedix’s products extract data from natural physician-patient conversations and convert it to medical notes in real time, which are seamlessly transferred to the EHR. To achieve this, the company’s Ambient Automation Platform uses Automated Speech Recognition and Natural Language Processing, supported by medical documentation specialists.
Leveraging this platform, Augmedix’s products relieve clinicians of administrative burden, in turn, reducing burnout and increasing both clinician and patient satisfaction. Augmedix is also leading the revolution in leveraging point-of-care data by making connections between millions of physician-patient interactions and analyzing them to deliver actionable insights that elevate patient care.
Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit augmedix.com.
Contact Information
Investors:
Matt Chesler, CFA
FNK IR
(646) 809-2183
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Kaila Grafeman
Augmedix
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.35 |
| Daily Volume: | 0 |
| Market Cap: | US$116.160M |
August 12, 2024 July 19, 2024 April 24, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
